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Abstract: Diabetics have a prothrombotic state that includes increased platelet reactivity. This 
contributes to the less favorable clinical outcomes observed in diabetics experiencing acute 
coronary syndromes as well as stable coronary artery disease. Many diabetics are relatively 
resistant to or have insufficient response to several antithrombotic agents. In the setting of 
percutaneous coronary intervention, hyporesponsiveness to clopidogrel is particularly common 
among diabetics. Several strategies have been examined to further enhance the benefits of oral 
antiplatelet therapy in diabetics. These include increasing the dose of clopidogrel, triple antiplatelet 
therapy with cilostazol, and new agents such as prasugrel. The large TRITON TIMI 38 randomized 
trial compared clopidogrel to prasugrel in the setting of percutaneous coronary intervention 
for acute coronary syndromes. The diabetic subgroup (n = 3146) experienced considerable 
incremental benefit with a 4.8% reduction in cardiovascular death, nonfatal myocardial infarction, 
and nonfatal stroke at 15-month follow-up with prasugrel treatment. Among diabetics on insulin 
this combined endpoint was reduced by 7.9% at 15 months. Major bleeding was not increased 
in the diabetic subgroup. This confirms the general hypothesis that more potent oral antiplatelet 
therapy can partially overcome the prothrombotic milieu and safely improve important clinical 
outcomes in diabetics.
Keywords: percutaneous coronary intervention, acute coronary syndromes, diabetes mellitus, 
prasugrel, antithrombotic agents
Scope of the problem
The prevalence of diabetes mellitus in individuals with coronary artery disease is 
estimated to be 14.8% in developed countries. Among those presenting with acute 
coronary syndromes or undergoing percutaneous coronary intervention (PCI), the 
prevalence of diabetes mellitus is estimated at 30% and 26%, respectively.1,2 Similarly, 
the prevalence of diabetes mellitus among patients undergoing coronary artery bypass 
graft surgery in the United States between 1990 to 2000 was estimated at 30% in the 
Society for Thoracic Surgeons registry.3
Often aptly referred to as the “diabetes disadvantage,” diabetics have inferior 
outcomes compared to non-diabetics across the spectrum of cardiovascular 
presentations and procedures. For example, after adjusting for other baseline and 
treatment differences in the pooled Thrombolysis In Myocardial Infarction (TIMI) 
trials from 1997 to 2006, diabetes independently and significantly conferred a 
78% increased risk of 30-day mortality in unstable angina (UA)/non-ST-segment 
mycocardial infarction (NSTEMI) patients and a 40% increased 30-day mortality in 
those with STEMI. At 1 year, the excess mortality risk independently attributed to Vascular Health and Risk Management 2011:7 446
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diabetes was 65% and 22%, respectively for UA/NSTEMI 
and STEMI.4 In the PCI arena, multiple reports have 
noted significantly higher rates of stent thrombosis among 
diabetics, even after adjusting for vessel diameter and 
implanted stent length. In the large multicenter EVASTENT 
registry of largely on-label sirolimus eluting stent use, the 
rate of drug-eluting stent thrombosis was 4.3% among 
diabetics (vs 3.0% in nondiabetics) with multivessel disease 
and 3.2% (vs 1.7% in nondiabetics) with single vessel 
disease at 1-year follow-up.5 Among diabetics, insulin-
requiring diabetes was an additional independent risk factor 
for stent thrombosis.
Vascular pathophysiology  
in diabetes mellitus
In addition to a greater burden of atherosclerotic disease 
and more co-morbidities, diabetics have a prothrombotic 
state. Multiple factors have been either demonstrated or 
hypothesized to have a causative role in the etiology of 
this greater thrombotic risk. These include endothelial 
dysfunction, impaired coagulation function, depressed 
fibrinolysis, and impaired platelet function.6–8
The endothelium of diabetics has increased “stickiness”, 
likely from greater expression of adhesion molecules such 
as vascular cell adhesion molecule 1 (VCAM-1), decreased 
nitric oxide (NO) generation, and increased interaction 
between the endothelium and inflammatory leukocytes.9 
Greater oxidative stress in diabetes results in induction 
of nuclear factor kappa-light-chain-enhancer of activated 
B cells (NFκB), a rapid response transcription factor that 
regulates the inflammatory immune response to numerous 
noxious stimuli.10 Decreased NO elaboration and increased 
production of the potent vasoconstrictor endothelin-1 (ET-1) 
impair normal vasodilatation.11,12 These mechanisms likely 
account for the impaired endothelium-dependent dilation of 
the brachial artery observed in diabetics.13,14
Diabetics have been documented to have higher levels 
of fibrinogen, von Willebrand factor (vWF), factor VII, 
factor VIII, and thrombin generation.15,16 Counter regulatory 
levels of antithrombin III and sulfated heparins are also 
lower. Similarly, diabetics have been documented to have 
lower levels of tissue plasminogen activator (t-PA) as well as 
elevated plasma levels of plasminogen activator inhibitor-1 
(PAI-1) and α-2 antiplasmin, likely accounting for the obser-
vation of relatively impaired endogenous fibrinolysis.17–19
Platelet  dysfunction  in  diabetics  leads  to 
hyper-responsiveness to platelet agonists and subsequent 
increases in pathological platelet activation and aggregation 
(Table 1).8,20 In a study of 257 diabetics with coronary artery 
disease (CAD) compared to 565 nondiabetics with CAD, 
Serebruany et al measured significantly higher baseline 
aggregatory response to the agonists adensone diphosphate 
(ADP) and collagen by light transmittance aggregometry, 
the Ultegra Rapid Platelet Function Analyzer, and the Sie-
mens PFA-100 analyzer.21 Diabetics have greater expression 
of platelet and endothelial cell adhesion molecules such as 
platelet endothelial call adhesion molecule-1 (PECAM-1) and 
VCAM-1.22 Diabetics have higher levels of GP IIb/IIIa antigen 
and activity. Diabetics have more vitronectin receptors and 
intact epitope of the protease-activated receptor-1 (PAR-1) 
thrombin receptor. Diabetics have higher plasma levels 
of the soluble 100-kD P-selectin fragment and P-selectin 
upregulation and expression on platelets, indicating a higher 
baseline state of platelet activation.23,24 Soluble CD40 ligand 
levels are also elevated in diabetics. Activated platelets express 
and release CD40 ligand which induces endothelial cells to 
secrete chemokines and to express adhesion molecules that 
recruit leukocytes, causing inflammation of the vessel wall.25 
Table 1 Platelet abnormalities seen in diabetics8
•  increased thromboxane A2 production
•    increased platelet activation due to increased surface adhesion molecules expression (CD31, CD62P, CD63) vitronectin receptors and intact 
epitope of the PAR-1 thrombin receptor
•  increased expression of platelet and endothelial cell adhesion molecules (PeCAM-1 and VCAM)
•  increased expression of platelet surface receptors (P-selectin, GP ib, GP iiBiiiA)
•  increased platelet mediated thrombin generation
•  increased platelet hypersensitivity to agonists (ADP, collagen, thrombin, platelet activating factor)
•  Decreased platelet sensitivity to PGi2 and nitric oxide
•  Reduced endothelial synthesis of PGi2 and nitric oxide
•  Accelerated thrombopoesis or platelet turnover resulting in generation of fresh and hyper reactive platelets
•  Increase production of proinflammatory and proatherogenic cytokines and chemokines (platelet factor 4, interleukin 1β, CD40 L)
•  Abnormal platelet calcium and magnesium homeostasis resulting in platelet hyperactivity, hyperaggregability, and adhesivenessVascular Health and Risk Management 2011:7 447
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Prasugrel oral antiplatelet therapy in DM
Accelerated platelet turnover may also occur in diabetics 
with vascular disease.26 These new platelets entering the 
circulation may diminish the effectiveness of some agents 
such as aspirin.
Reading almost like a laundry list, the diabetic’s 
vascular pathophysiology is admittedly complex and not 
fully elucidated. While all the precise inter-relationships 
and their relative importance are uncertain, the distribution 
of numerous important parameters of endothelial and 
thrombotic function and control in diabetics is dissimilar 
to the nondiabetic norm. From a clinical perspective, the 
multifactorial nature of this dysregulation helps explain the 
less optimal outcomes (diabetes disadvantage) we observe 
in our practices. It also emphasizes that the outcomes 
in diabetics, as demonstrated in TRITON TIMI 38 with 
prasugrel, are more contingent upon optimal antiplatelet 
and antithrombin therapy.
Given this prothrombotic state and increased baseline 
risk, randomized trials and meta-analyses have generally 
documented greater absolute benefit from both oral and 
parenteral antiplatelet therapy in diabetic patients with 
acute coronary syndromes compared to nondiabetics. Our 
currently available oral agents with significant antiplatelet 
activity are aspirin, ticlopidine, clopidogrel, and cilostazol. 
Prasugrel, a potent third-generation thienopyridine, has 
recently been added to our therapeutic options. The addi-
tional agents ticagrelor, elinogrel, and cangrelor as well as 
oral thrombin receptor antagonists will likely be approved 
for non-experimental use in the coming years. A brief review 
of the efficacy and limitations of existing agents delineates 
the need for more consistently effective agents.
Aspirin for primary and secondary 
prevention in diabetics
Aspirin irreversibly inhibits the COX1 enzyme needed for 
the production of TXA2 thus reducing platelet aggregation. 
Aspirin has not been proven to be beneficial for primary 
prevention of cardiovascular events in diabetics without 
other risk factors (perhaps because of inadequately powered 
trials).27,28 In contrast, the role of oral antiplatelet therapy 
for secondary prevention in diabetics with a history of 
atherothrombotic events is firmly established. The antiplatelet 
trialists collaborative individual patient data meta-analysis 
demonstrated a reduction of 38 ± 12 (SD) events per 1000 
high-risk diabetics (history of myocardial infarction [MI], 
UA, cerebrovascular accident [CVA], or transient ischemic 
attack [TIA]) treated with an antiplatelet agent, mostly aspirin 
(P  0.002).29
Clopidogrel for secondary 
prevention in diabetes
Inhibiting the platelet P2Y12 receptor also reduces platelet 
activation and aggregation. In the CAPRIE trial that compared 
the second-generation thienopyridine clopidogrel to aspirin 
therapy in patients with recent ischemic stroke, recent MI, or 
established peripheral arterial disease, clopidogrel reduced 
the 1-year ischemic events compared to aspirin from 12.7% 
to 11.8% (P = 0.096) and from 17.7% to 15.6% in a subgroup 
of 3866 patients with diabetes mellitus (P = 0.042).30,31 
In the PLUTO diabetes trial, 1 month treatment with aspirin 
and clopidogrel provided greater platelet inhibition as 
measured by various platelet function tests compared with 
treatment with aspirin alone.32 In the landmark CURE trial, 
acute coronary syndrome patients without ST elevation 
were randomized to clopidogrel vs placebo superimposed 
on background aspirin therapy. 2849 of the 12,562 patients 
enrolled in CURE were diabetic. The diabetic subgroup 
had a 1-year event rate (cardiovascular death, MI, CVA) of 
14.2% with dual antiplatelet therapy compared to 16.75% 
with aspirin monotherapy.33 Although this reduction in events 
in the diabetic subgroup alone did not quite reach statistical 
significance, the point estimate of benefit was greater among 
diabetics than nondiabetics. The absolute 1% increase in 
major bleeding to 3.7% with dual antiplatelet therapy vs 2.7% 
with aspirin alone (relative risk [RR] 1.38, 95% CI 1.13 to 
1.67, P = 0.001) should be assumed to apply to the diabetic 
subgroup as well.
In all, 7 large scale trials have evaluated dual antiplate-
let therapy with clopidogrel and aspirin vs monotherapy 
with either clopidogrel or aspirin alone. Mostly secondary 
prevention trials except for the multiple-risk-factor group 
in CHARISMA, the clinical indications have ranged from 
acute coronary syndromes (ACS) to peripheral vascular and 
cerebrovascular diseases. A substantial portion of the enrolled 
patients were diabetic. Where reported, the outcomes for 
diabetics vs nondiabetics by treatment strategy are outlined 
in Table 2.
Glycoprotein inhibitor use  
in diabetics
Although not directly inhibiting platelet activation, the 
familiar glycoprotein IIb/IIIa receptor antagonists like 
abciximab, eptifibatide, and tirofiban markedly reduce platelet 
aggregation by preventing cross-linking between activated 
platelets. Blocking the IIb/IIIa receptors prevents binding 
to vWF and fibrin. A meta-analysis of the randomized trials 
of IIb/IIIa agents vs placebo in non-STE ACS demonstrated Vascular Health and Risk Management 2011:7 448
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a 30-day mortality reduction from 6.2% with placebo to 
4.6% with IIb/IIIa agents at 30 days in the 6458 diabetes 
patients enrolled in PRISM, PRISM-PLUS, PARAGON 
A, PARAGON B, PURSUIT, and GUSTO IV (odds ratio 
[OR] 0.74, 95% CI 0.59 to 0.92, P = 0.007). Among the 
23,072 nondiabetes patients 30-day mortality was 3.0% in 
both IIb/IIIa and placebo groups. Among the 1279 diabetics 
undergoing PCI, 30-day mortality was 1.2% with IIb/IIIa 
therapy and 4.0% with placebo (OR = 0.30; 95% CI 0.14 to 
0.69, P = 0.002).34 Broadly applied, these current treatments 
have almost certainly significantly improved the outcomes 
of diabetics suffering ACS. The clinical results in diabetics 
of powerfully inhibiting platelet aggregation with parenteral 
glycoprotein IIb/IIIa receptor antagonists may provide a 
foretaste of the potential incremental efficacy results that 
may be expected with more potent oral agents than aspirin 
and clopidogrel.
Resistance to antiplatelet therapy  
in diabetes
While diabetics are at higher baseline risk and thus potentially 
have more to gain from effective therapies, diabetics also 
have relatively less intrinsic response to many current 
antithrombotic agents. This likely reflects the diabetic’s 
prothrombotic milieu described above. Diabetics have been 
documented to have less antiplatelet response to both aspirin 
and clopidogrel as well as less antithrombotic response to the 
indirect thrombin inhibitors enoxaperin and unfractionated 
heparin.35
Examining platelet inhibition as measured by light trans-
mittance aggregometry (LTA) with 20 µM ADP at 24 hours 
after a 300 mg clopidogrel load, Angigillo demonstrated that 
38% of diabetics had 10% platelet inhibition compared 
to 8% of nondiabetics.36 Similarly, another 6% of diabetics 
were low (10% to 29% inhibition) responders. In total, 44% 
of diabetic were non- or low-responders compared to 22% 
of nondiabetics. In the maintenance phase with 75 mg of 
clopidogrel daily, mean in vitro platelet inhibition to 20 µM 
or 6 µM of ADP was also significantly lower in diabetics than 
nondiabetics. Among similar patients with CAD, Serebrauny 
et al have demonstrated that diabetics have less response 
to aspirin and clopidogrel as measured by several different 
assays of platelet function.21
Low platelet inhibitory response as measured by multiple 
assays has now been definitively linked to increased risk of 
clinical events such as stent thrombosis. A meta-analysis 
of 20 studies in 2930 patients using LTA, VerifyNow®, 
PFA-100, thromboelastogram, and vasodilatator stimulated 
phosphoprotein phosphorylation index (VASP-P Index) demon-
strates a summary OR of 3.85 (95% CI 3.08 to 4.80) for adverse 
clinical ischemic events among patients with low response to 
aspirin.37 Low response to clopidogrel has now also been linked 
to increased events. In a study of 173 type 2 diabetics with CAD, 
Angiolillo and others observed a 37.8% rate of major adverse 
cardiovascular events at 2 years follow-up in low responders to 
clopidogrel compared to 13.2%, P  0.001, in the more robust 
responders.38 A large (n = 1608) study from Munich in unse-
lected patients undergoing PCI using the multiplate analyzer 
conclusively demonstrated that patients in the lowest quintile 
of platelet response to clopidogrel are at increased risk of 
stent thrombosis. The 30-day definite stent thrombosis rate 
in the lowest quintile of response was 2.2% compared to 0.2% 
in the other four “normal responding” quintiles (P = 0.0001). 
The combined death and stent thrombosis rates were 3.1% 
and 0.6%, respectively. There was a nonsignificant trend to 
increased bleeding in the quintile with the greatest platelet 
response.39 In a randomized trial comparing proceeding to PCI 
after 600 mg clopidogrel load vs one or more reloads if platelet 
response was subtherapeutic as measured by the VASP index, 
Bonello et al demonstrated a lower clinical event rate with 
platelet function assay guided clopidogrel therapy.40
The GRAVITAS trial failed to show a clinically significant 
benefit to increasing the maintenance dose of clopidogrel to 
150 mg daily in low responders to the loading dose as measured 
by the VerifyNow® assay. Rather than disproving the concept 
of platelet functional test guided therapy, GRAVITAS suggests 
simply doubling the maintenance  dose is an inadequate therapy 
for most clopidogrel low responders42
Hyporesponsivess to antithrombins: 
implications for oral antiplatelet 
therapy in diabetics
In addition to higher baseline risk and low response to 
antiplatelet therapy, relative hyporesponsiveness of diabetics 
to indirect thrombin inhibitors also may contribute to the 
observations in the ExTRACT TIMI 25 study.41 Diabetics 
suffering a STEMI had substantially higher 30-day mortality 
than non-diabetics with either enoxaperin or unfractionated 
heparin. Diabetics assigned to enoxaperin, however, had 
lower 30-day mortality than with unfractionated heparin 
(P = 0.039). This implies that more effective thrombin 
inhibition, whether due to an intrinsically more active agent 
or simply an agent permitting a greater proportion of the 
treated to rapidly achieve therapeutic effect, is particularly 
salutary in diabetics. Given that thrombin is the most potent Vascular Health and Risk Management 2011:7 450
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in vivo activator of platelets, perhaps additional approaches to 
overcome thrombin would include more effective antiplatelet 
therapy in the forms of greater P2Y12 and/or PAR1 thrombin 
receptor inhibition. By reducing the impact of any activated 
thrombin that escapes anti-thrombin therapy, more potent 
antiplatelet agents help mitigate any shortcomings of the 
antithrombin agents in diabetics.43
Given the pivotal thrombin-platelet activation interaction 
in thrombosis, the ACUITY trial provides some insight 
into the particular importance of adequate inhibition of 
this thrombotic axis in diabetics.44 The direct thrombin 
inhibitor bivalirudin has the mechanistic advantage of more 
powerful inhibition of clot-bound thrombin compared to 
unfractionated heparin and low-molecular-weight heparin. 
In patients presenting with UA/NSTEMI/ACS receiving 
background aspirin therapy and clopidogrel treatment 
timed at the discretion of the investigator’s local practice 
pattern, the ACUITY randomized trial tested the strategies 
of bivalirudin monotherapy vs unfractionated heparin 
(UFH) or enoxaperin coupled with routine IIb/IIIa receptor 
antagonist administration in patients with UA/NSTEMI/
ACS. In the diabetic subgroup (n = 2585), numerically fewer 
ischemic outcomes were observed at 30 days with bivalirudin 
monotherapy, 7.8%, compared to 8.8% with the strategy of 
indirect thrombin inhibitors (UFH or enoxaperin) combined 
with routine intravenous IIb/IIIa inhibitor. While this differ-
ence was not statistically significant (P = 0.39), it is mecha-
nistically interesting that more potent antithrombin therapy 
alone performed equally well to IIb/IIIa receptor inhibition 
for ischemic outcomes in diabetics. Hence, more effective 
inhibition of the key in vivo platelet agonist thrombin is of 
great utility in diabetics. Noncoronary artery bypass grafting 
(CABG) related major bleeding was substantially lower with 
the direct thrombin inhibitor (bivalirudin) strategy at 3.7% vs 
7.1% with UFH or enoxaperin with routine IIb/IIIa therapy 
(P = 0.0002). Hence, the net clinical outcome combining 
composite ischemic events and major bleeding was supe-
rior (P = 0.02) for bivalirudin (10.8%) vs indirect thrombin 
inhibitor with routine IIb/IIIa (13.7%) in the setting of an 
early invasive strategy to manage non-ST elevation ACS in 
diabetics. This result for a direct thrombin inhibitor compared 
to routine IIb/IIIa therapy is particularly impressive given the 
variability of administration of dual oral antiplatelet therapy 
in this carefully double-blinded trial. While background 
aspirin therapy was near universal, the timing and dosing 
of clopidogrel was consistent with routine practice. Hence, 
many patients received clopidogrel on the table only once the 
anatomy was defined or after PCI.45 Given this understandable 
reluctance to pre-treat with clopidogrel until the anatomy is 
defined and ascertained to be nonsurgical, a more rapidly 
effective and consistently therapeutic agent than clopidogrel 
without excess bleeding would be desirable.
Given that many diabetics are low responders to 
clopidogrel, the ACUITY diabetic subgroup data generate the 
promising hypothesis that a P2Y12 receptor antagonist such 
as prasugrel with more rapid, potent, and consistent platelet 
inhibition may further enhance the ischemic benefit of the 
bivalirudin monotherapy strategy in diabetics. Hopefully, 
this would remain without increased “bleeding penalty” as 
observed in the diabetic subgroup of TRITON TIMI-38 with 
prasugrel (n = 3146). The non-CABG TIMI major bleeding 
rate at 450 days was similarly low at 2.5% with the more 
potent agent prasugrel as clopidogrel at 2.6% despite their 
combined use with unfractionated heparin, enoxaperin, and 
IIb/IIIa use in 53%. Perhaps the major bleeding rates would 
be even lower with bivalirudin than the indirect thrombin 
inhibitors as observed in the Bivalirudin Angioplasty Trial 
and lower than indirect thrombin inhibitors combined with 
IIb/IIIa therapy as observed in REPLACE2, ACUITY, and 
HORIZONS-AMI.46–49
Prasugrel’s more potent  
antiplatelet effects
TIMI 44 examined the effect of prasugrel on platelet func-
tion compared to clopidogrel in 201 patients undergoing 
elective cardiac catheterization for possible PCI.50 Of the 
patients in TIMI 44, 30.8% were diabetic. In a randomized, 
double-blind, cross-over design, patients received either a 
600 mg loading dose of clopidogrel or 60 mg of prasugrel. 
The primary endpoint was inhibition of platelet aggregation 
to 20 µM ADP at 6 hours after the loading dose. This was 
74.8% ± 13.0% with prasugrel and 31.8% ± 21.1% with 
clopidogrel (P  0.0001) (Figure 1). As early as 30 minutes 
after the loading dose, inhibition of platelet aggregation 
(IPA) was 30.8% ± 29.0% with prasugrel and only 4.9% 
± 13.0% with clopidogrel (P  0.0001). At the other 
timepoints of 2 and 18 to 24 hours, the degree of platelet 
inhibition remained markedly different favoring prasugrel. 
Similar results were observed with the VASP platelet reac-
tivity index. A VASP platelet reactivity index of 50% is 
generally considered therapeutic and has been associated 
with a very low probability of ischemic complications sur-
rounding PCI.
Among the 112 patients that proceeded to PCI, a 
maintenance dose of 10 mg of prasugrel was compared to 
150 mg of clopidogrel. Again the endpoint at 14 days was IPA Vascular Health and Risk Management 2011:7 451
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Figure 1 inhibition of platelet aggregation (iPA) with 600 mg loading dose of clopidogrel vs 60 mg of prasugrel in TiMi-44. (A) As measured by 20 µM adenosine diphosphate 
(ADP) with light transmittance aggregometry and (B) with the vasodilatator stimulated phosphoprotein index (VASP)-platelet reactivity index %. Copyright © 2007.   wolters 
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to 20 µM ADP. IPA was 61.3% ± 17.8% with prasugrel and 
46.1% ± 21.3% with clopidogrel (P  0.0001). (Figure 2) 
At day 15, the patients in the maintenance phase were crossed 
over to the other agent and platelet function was reassessed at 
29 days. This demonstrated essentially reversal of the degree 
of platelet inhibition between the crossed over groups. The 
former prasugrel group’s IPA dropped to 46.8% ± 13.2% on 
clopidogrel. The former clopidogrel group’s IPA increased 
to 60.8% ± 15.9% with prasugrel (P  0.0001). TIMI 
44 conclusively demonstrated a more rapid, potent, and 
consistent platelet inhibition with 60 mg loading dose 
and 10 mg maintenance dose of prasugrel compared with 
a 600 mg loading dose and 150 mg maintenance dose of 
clopidogrel. In addition to the primary endpoint of IPA 
to 20 µM ADP, TIMI 44 documented qualitatively and 
quantitatively similar results with other platelet function 
tests and agonist concentrations. These included maximal 
platelet aggregation with light transmittance aggregometry 
at 5 µM ADP, VASP index, and the VerifyNow® point-of-
care P2Y12 assay.
Both thienopyridines are prodrugs whose active 
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active metabolites bind covalently with disulfide bonds to 
cysteine residues of the platelet P2Y12 receptor inhibiting 
its interaction with stimulatory ADP. This irreversible 
binding then inhibits platelets for the remainder of their 7- to 
10-day lifespan. The in vivo platelet function and clinical 
differences between prasugrel and clopidogrel arise from 
differences in the efficiency of generation of their active 
metabolites. Once generated, the active metabolites have 
similar intrinsic potencies to inhibit ADP interaction with 
the P2Y12 receptor.51
Once orally administered and absorbed, esterases 
convert approximately 85% of the administered clopi-
dogrel molecules to an inactive metabolite (Figure 3). 
The remainder of the prodrug is biotransformed into 
its active metabolite by two cytochrome P-450 (CYP) 
dependent oxidative steps. CYP polymorphisms affect the 
efficiency of these conversions and the ultimate degree 
of platelet inhibition. In particular the CYP2CI9*2 allele 
has been demonstrated to have reduced area under the 
plasma concentration–time curve for the active metabolite Vascular Health and Risk Management 2011:7 453
Prasugrel oral antiplatelet therapy in DM Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
of clopidogrel as well as significantly lower reduction in 
maximal platelet aggregation.52,53 Approximately 30% of 
Whites, 40% of Blacks, and 55% of East Asians carry at 
least 1 copy of the CYP2C19 reduced-function allele. In the 
TRITON TIMI-38 study, patients with a reduced-function 
CYP2C19 allele randomized to clopidogrel experienced a 
53% higher rate of cardiovascular death, nonfatal MI, or 
stroke compared to noncarriers (12.1% vs 8.0%, HR 1.53, 
95% CI 1.07 to 2.19, P = .01). The HR for stent thrombosis 
was 3.09 with stent thrombosis rate of 2.6% for carriers vs 
0.8% for noncarriers, P = 0.02, at 450 days, albeit most 
events occurred early in the first 30 days (Figure 4).
In addition to important genetic variations in the 
efficiency of enzymatic metabolism required to biotransform 
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clopidogrel to its active metabolite, there may be clinically 
important drug–drug interactions that may also reduce the 
ultimate concentration of the active metabolite. Some proton 
pump inhibitors, for instance, further reduce plasma concen-
trations of the active metabolite required for effective P2Y12 
receptor inhibition. Retrospective studies in Canadian and 
Veterans Affairs databases have now drawn an association 
between co-administration of some proton pump inhibitors 
and higher post-PCI ischemic event rates.54,55
Prasugrel on the other hand rapidly undergoes biotrans-
formation. It is quickly hydrolyzed by carboxylesterases to a 
thiolactone (2-oxo-prasugrel (R-95913)) and then converted 
to its active metabolite (R-138727 with cleaved heterocyclic 
5-member ring) by multiple cytochrome P450 isotopes. 
This biotransformation appears to be consistent, rapid, and 
efficient in all patients tested to date.56 Wallentin et al have 
demonstrated a much larger area under the curve of active 
metabolite for a loading dose of 60 mg of prasugrel compared 
to 600 mg of clopidogrel with correspondingly much lower 
residual platelet reactivity in the prasugrel-treated patients.57 
Similarly, Brandt et al in a cross-over design, have demon-
strated in healthy volunteers that the nonresponders to a 
300 mg clopidogrel loading dose all respond to a 60 mg load 
of prasugrel as measured by turbidometric aggregometry.58
Prasugrel’s clinical effectiveness  
in diabetics
The clinic implications of these differences in the phar-
macokinetics and pharmacodynamics of prasugrel vs 
clopidogrel have been evaluated in the landmark TRI-
TON-TIMI 38 study. (58) STEMI (2900) and NSTE/ACS 
(10,000) patients undergoing an invasive strategy were 
randomized to clopidogrel 300 mg load with 75 mg main-
tenance vs prasugrel 60 mg load and 10 mg maintenance. 
A significant 19% reduction in cardiovascular death, MI, 
and stroke was observed with prasugrel at 450 days (9.9%) 
compared to clopidogrel (12.1%), P = 0.0004. Non-CABG 
TIMI major bleeding increased 32% from 1.8% with 
clopidogrel to 2.4% with prasugrel, P = 0.03. Combining 
these endpoints, the majority of patient subgroups had 
better outcomes with prasugrel. Exceptions were patients 
weighing 60 kg and patients 75 years old, where the 
outcomes were equal. Patients with prior TIA or CVA did 
worse with prasugrel.
TRITON-TIMI 38 included 3146 diabetics.60 Perhaps 
because of their higher baseline risk and prothrombotic state, 
the diabetic subgroup reaped particular benefit from the more 
potent agent. At 450 days follow-up, there was a 30% significant 
reduction (HR 0.70) in cardiovascular death, MI, and stroke 
with prasugrel at 12.2% compared to 17.0% with clopidogrel, 
P  0.001 (Figure 5). Most of this difference occurred in the 
first 30 days but there continued to be increasing separation 
of the event curves over the next 420 days. For every 21 
diabetic patients treated with prasugrel instead of clopidogrel, 
one major ischemic event was prevented. No difference was 
observed in non-CABG TIMI major bleeding with a rate of 
2.5% with prasugrel and 2.6% with clopidogrel (Figure 5, 
panel D). The combination of TIMI major or minor bleeding 
was numerically higher with prasugrel at 5.3% vs 4.3% but 
not significantly different, P = 0.13.
Whereas nondiabetics experienced a 14% reduction in 
the composite ischemic event rate with prasugrel compared 
to clopidogrel, this reduction was 26% in diabetics not requir-
ing insulin, and 37% in those treated with insulin. Enhanced 
outcomes in diabetics with a more potent inhibitor of platelet 
activation and aggregation fits given the mechanisms of the 
diabetic prothrombotic state. From a practice standpoint, the 
precautions for increased bleeding risk from the overall trial 
(history of TIA/CVA, age  75, or body weight  60 kg) 
should be considered to apply to the diabetic subgroup since no 
significant interaction (P = 0.29) was observed between treat-
ment and diabetes status for major hemorrhage. Ultimately, 
the dosing of prasugrel may need to be individualized.
Large retrospective analyses have generally not identified 
diabetes mellitus as a prominent, independent risk factor for 
bleeding surrounding PCI. For example, the ACC-National 
Cardiovascular Data Registry CathPCI Registry bleeding 
prediction model examining 302,152 patients did not find 
that diabetics had a significantly elevated risk of bleeding. 
Diabetes was also not an independent predictor of bleeding. 
In the TRIOLOGY trial, a 5 mg dose of prasugrel will be 
prospectively tested in high bleeding risk patients.61
Prasugrel will be an important new addition to our arma-
mentarium of antiplatelet agents in clinical cardiovascular 
practice for many subsets of patients, particularly diabetics. 
While TRITON-TIMI 38 supports the use of prasugrel in 
most patients presenting with an acute coronary syndrome 
undergoing PCI, there will likely remain a significant role 
for both established and other new antiplatelet agents. These 
are expected to include the oral nonthienopyridine P2Y12 
receptor antagonist ticagrelor (AZD-6140), the intravenous 
rapidly reversible modified adenosine triphosphate analogue 
cangrelor that anatagonizes ADP-induced activation of the 
P2Y12 receptor, the oral or intravenous agent elinogrel, 
and oral PAR-1 thrombin receptor antagonists such as 
SCH530348 and E5555.Vascular Health and Risk Management 2011:7 455
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Alternative regimens to consider  
in diabetics
In routine clinical practice there will likely remain a neces-
sity for alternative regimens to prasugrel particularly in 
the identified subgroups in TRITON-TIMI 38. Specifically 
weight  60 kg, and age  75 patients (17% of the study 
population) had no incremental benefit from prasugrel. 
Patients with a history of prior TIA or CVA (another 4% of the 
study population) did worse with prasugrel than clopidogrel. 
Since prasugrel was not superior to clopidogrel in these 
subgroups, this naturally raised the question of whether 
clopidogrel is superior to placebo in these same subgroups. 
The CURE investigators have re-examined these subgroups 
identified in TRITON-TIMI 38. In the CURE trial, these 
subgroups did better with dual antiplatelet therapy in the form 
of clopidogrel and aspirin than placebo and aspirin.
In addition to these subgroups identified in TRITON, there 
will certainly be other high-bleeding risk patients identified 
in routine practice. They will likely need dose reductions of 
prasugrel or alternative regimens, particularly for chronic 
maintenance therapy. Other real world constraints such as the 
commonly encountered economic constraint with clopidogrel 
will probably also dictate alternative regimens. When the 
exclusive patent on Plavix® expires, generic clopidogrel may 
be the only economically feasible agent for many patients, 
particularly those with documented therapeutic response on 
functional testing.
Strategies we and others have employed in our practices 
for high-risk patients have included maintenance doses of 
150 mg of clopidogrel (albeit GRAVITAS now suggests 
this may be insufficient) and/or triple antiplatelet therapy 
with clopidogrel, aspirin, and cilostazol. High-risk patients 
have been identified based on both clinical and angiographic 
characteristics. Diabetics, high body mass index patients, 
those previously treated with brachytherapy, and hypore-
sponders as measured by platelet function assays should be 
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considered for more intensive therapy.62,63 In patients with a 
prior history of stent thrombosis and intravascular ultrasound 
confirmation of adequate deployment of the initial stent as 
well as compliance with dual antiplatelet therapy, certainly 
more aggressive and platelet function assay guided antiplate-
let therapy seems advisable. Anatomic indications in our 
practice for higher doses of clopidogrel, platelet function 
assays, or triple antiplatelet therapy have been bifurcational 
stenting, multivessel stenting, long overlapping stents, small 
diameter vessels, unprotected left main stenting, and last 
patent vessel/graft anatomies.
A 600 mg loading dose of clopidogrel is no longer con-
troversial given a meta-analysis of the 10 randomized trials 
evaluating this issue.64 Lotrointe et al demonstrate an OR of 
cardiac death or nonfatal myocardial infarction of 0.54 (95% 
CI 0.32 to 0.90) with a 600 mg load compared to 300 mg. 
There was no significant increase in bleeding. In addition to 
TIMI-44, other data is evolving to support a higher mainte-
nance dose of clopidogrel in some subsets including diabet-
ics. The Optimal Antiplatelet Therapy in Diabetes Mellitus 
study (OPTIMUS) evaluated the functional impact of an 
150 mg maintenance dose of clopidogrel in diabetics.65,66 
Diabetics were randomized to a 75 or 150 mg maintenance 
dose of clopidogrel. Platelet aggregation was significantly 
reduced with the higher dose. However, 60% of the diabetics 
on the 150 mg regimen remained in the suboptimal response 
range. The efficacy and safety of this higher maintenance 
dose has been prospectively evaluated (GRAVITAS). The 
lack of significant clinical response to 150 mg maintenance 
dose confirms that this remains an insufficient therapy in 
many clopidogrel hyporesponders.
Recent data confirms the utility of triple antiplatelet 
therapy (aspirin, clopidogrel, and cilostazol) in some patients 
including diabetics. The Optimal Antiplatelet Therapy in 
Diabetes Mellitus 2 study (OPTIMUS-2) demonstrates 
enhanced platelet inhibition when cilostazol is added to 
aspirin and clopidogrel therapy.67 Lee et al have demonstrated 
reduced stent thrombosis and improved clinical outcomes 
with triple antiplatelet therapy in the DECLARE-Long 
study.68 A randomized trial in 1212 patients with ACS, 
randomly assigned patients to standard dual-antiplatelet 
treatment (aspirin and clopidogrel) or triple-antiplatelet 
therapy with the addition of a 6-month course of cilostazol 
after successful PCI. The primary endpoint was a composite 
of cardiac death, nonfatal MI, stroke, or target vessel revas-
cularization (TVR) at 1 year. Triple-antiplatelet treatment 
was associated with a significantly lower incidence of the 
primary end points (10.3% vs 15.1%; P = 0.011). The need 
for TVR was similar between both regimens (7.9% vs 10.7%; 
P = 0.10). Female patients and clinically or angiographically 
high-risk patients benefited more from the triple-antiplatelet 
treatment. There were no significant differences in major or 
minor bleeding between the 2 regimens.(68) The CIlostazol 
after Drug-Eluting Stent in diabetics trial (CIDES) random-
ized 280 diabetics to either cilostazol and aspirin or clopi-
dogrel and aspirin after an initial month of triple therapy. 
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There was 1 stent thrombosis in each group by 7 months 
follow-up. The rate of angiographic restenosis (stent plus 
5-mm borders) was 9 (8.0%) in the cilostazol group and 20 
(16.1%) in the clopidogrel group, p = 0.041).70
At present, our antiplatelet therapy strategies are largely 
based upon overall and subgroup findings in large trials. 
Individual patient tailored therapy based on platelet function 
assays (PFAs) and perhaps genotyping will likely become the 
future standard of care as prospective trials evaluate these 
strategies including their incremental cost-effectiveness. 
A flow chart depicting the timing of PFA testing with adjust-
ments in therapy outlines our proposed practice with the 
addition of prasugrel (Figure 6). Until prospective validation 
of these approaches in RCTs, as with all medical practice, we 
will need to base treatment decisions on the applicable main 
and subgroup results of trials without individualized PFA 
evaluations.71 Potent new agents like prasugrel may obviate 
the need for platelet function assays to assess efficacy but may 
still be beneficial to predict safety. As always, supplementing 
these data with astute clinical judgment and patient-specific 
risk prediction instruments will undoubtedly further optimize 
individual patient outcomes.
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